TriSalus Life Sciences, Inc. (TLSI)

Over the past six months, TriSalus Life Sciences' stock has been impacted by several events. The company announced a public offering of common stock at $4.10 per share, raising $40.0 million. TriSalus reported strong commercial performance for Q4 and full-year 2025, with significant year-over-year revenue increases, but the stock declined following the earnings announcement. The company also reported its Q3 2025 results with a 57% year-over-year revenue increase. Preclinical research was published demonstrating enhanced delivery and immune activation with nelitolimod delivered via PEDD in liver tumor models. There was also insider selling by the Chief of Clinical Operations. The stock experienced a decline of 19.87% over the past six months. A Key Opinion Leader (KOL) event was held. TriSalus announced an exchange offer and consent solicitation related to its Series A Convertible Preferred Stock to streamline its capital structure.

There is no explicit mention of significant demand seasonality for TriSalus Life Sciences' products and services. Revenue growth is attributed to the expanding clinical adoption of its TriNav product suite and PEDD platform, as well as strategic initiatives. Management anticipates revenue growth to be weighted towards the second half of 2026 due to upfront commercial investments and the timing of new product contributions.

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that integrates drug delivery technologies with standard-of-care therapies and investigational immunotherapeutics. The company operates in the Healthcare sector, focusing on Medical Specialties, Drug Delivery, and Biotechnology. Its core business revolves around its Pressure-Enabled Drug Delivery (PEDD) approach, designed to improve therapeutic delivery to liver and pancreatic tumors. Major products include the TriNav Infusion System and TriNav Infusion System LV, used for hepatic arterial infusion, and a Pancreatic Retrograde Venous Infusion System, currently in Phase 1 clinical trial. TriSalus is also advancing nelitolimod, a clinical-stage investigational immunotherapeutic candidate.

TriSalus Life Sciences, Inc. is headquartered in Westminster, Colorado, United States, with operations and market focus primarily within the United States.

TriSalus Life Sciences has demonstrated a focus on advancing its medical technology and immunotherapy. The company reported strong commercial performance and exceeded its 2025 revenue guidance, indicating positive market reception for its TriNav product suite and PEDD platform. The publication of preclinical research showcasing enhanced delivery and immune activation with nelitolimod via PEDD also contributes positively to its scientific and medical standing. Analyst sentiment for TLSI is a "Hold" consensus, with an average price target suggesting significant upside potential.

TriSalus Life Sciences has a diverse ownership structure, with 75 institutional owners and shareholders holding a total of 11,417,277 shares. Major institutional owners include Nantahala Capital Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Institutions hold 38.2% of shares, individual insiders hold 13.1%, private companies hold 2.36%, and the general public holds 46.3%. Insider buying has exceeded insider selling in the past three months.